ChromaDex provides 2022 outlook: net sales +15-20% YoY; Tru Niagen revenue $56.7M in 2021

Niagen Bioscience, Inc.

2021 net sales $67.4M (+14% YoY); Tru Niagen sales $56.7M; gross margin 61.5%.
2022 guidance: net sales +15-20% YoY; gross margin ~60%; R&D spend up ~$2M; G&A down $5-6M.
E-commerce 62% of sales; partnerships expanded with Walmart US and Watsons; new SinoPharm partnership for China.
Cash $28.2M, zero debt; adjusted EBITDA excl. legal loss $(2.5)M in 2021; litigation expense largely behind.
Pipeline includes next-gen NAD precursors (NRH, NAR) with 10+ granted patents; 20+ clinical studies supporting NAD+ boosting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.